These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9293782)

  • 1. Adverse reactions to radiopharmaceuticals: the SNM/RSNA USP Drug Product Problem Reporting Program. Society of Nuclear Medicine/Radiological Society of North America. United States Pharmacopeial Convention.
    Silberstein EB
    J Nucl Med; 1997 Sep; 38(9):49N. PubMed ID: 9293782
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse reactions to radiopharmaceuticals: the RSNA-SNM-USP Drug Product Problem Reporting Program.
    Silberstein EB
    Radiology; 1997 Aug; 204(2):34A. PubMed ID: 9240510
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence of adverse reactions in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine.
    Silberstein EB; Ryan J
    J Nucl Med; 1996 Jan; 37(1):185-92. PubMed ID: 8543992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European system for reporting adverse reactions to and defects in radiopharmaceuticals: annual report 1999.
    Hesslewood SR
    Eur J Nucl Med; 2001 Feb; 28(2):BP2-8. PubMed ID: 11303900
    [No Abstract]   [Full Text] [Related]  

  • 5. The state of dietary supplement adverse event reporting in the United States.
    Gardiner P; Sarma DN; Low Dog T; Barrett ML; Chavez ML; Ko R; Mahady GB; Marles RJ; Pellicore LS; Giancaspro GI
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):962-70. PubMed ID: 18613260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine.
    Silberstein EB
    J Nucl Med; 1998 Dec; 39(12):2190-2. PubMed ID: 9867168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From the SNM Committee on Pharmacopeia: Exemption of radiopharmaceuticals from <797>.
    Hung JC;
    J Nucl Med; 2004 Oct; 45(10):13N, 16N. PubMed ID: 15551509
    [No Abstract]   [Full Text] [Related]  

  • 8. Surveillance of radiopharmaceuticals in Latin American: an alert.
    Santos-Oliveira R; Smith SW; de Souza Albernaz M; Bordim JA; Antunes LJ
    Rev Esp Med Nucl; 2011; 30(2):134-6. PubMed ID: 21334775
    [No Abstract]   [Full Text] [Related]  

  • 9. ACNP/SNM Government Relations Office midyear report: January-May 1998. American College of Nuclear Physicians/Society of Nuclear Medicine.
    Nichols D
    J Nucl Med; 1998 Jun; 39(6):24N-25N. PubMed ID: 9627320
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of US poison centers in adverse drug reactions monitoring.
    Chyka PA
    Vet Hum Toxicol; 1999 Dec; 41(6):400-2. PubMed ID: 10592954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European system for reporting adverse reactions to and defects in radiopharmaceuticals: annual report 2000.
    Hesslewood SE
    Eur J Nucl Med Mol Imaging; 2002 May; 29(5):BP13-9. PubMed ID: 11976816
    [No Abstract]   [Full Text] [Related]  

  • 13. USP--promoting the public health.
    Carothers N
    Todays Surg Nurse; 1998; 20(1):35-9. PubMed ID: 9866636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug reactions and reporting.
    Witte R
    Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
    [No Abstract]   [Full Text] [Related]  

  • 15. Positron emission tomography: a technology assessment of PET imaging--past, present, and future.
    Frazee D
    Radiol Manage; 2004; 26(6):38-43. PubMed ID: 15633509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving adverse drug reaction reporting in the community setting.
    McCloskey BA
    Med Interface; 1996 May; 9(5):85-7. PubMed ID: 10157690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European system for reporting adverse reactions to and defects in radiopharmaceuticals: annual report 1995.
    Eur J Nucl Med; 1996 Dec; 23(12):BP27-31. PubMed ID: 9005137
    [No Abstract]   [Full Text] [Related]  

  • 18. E-mail, snail mail, phone, or fax. Reporting adverse reactions and other product problems.
    Henkel J
    FDA Consum; 1998; 32(6):7-9. PubMed ID: 9854444
    [No Abstract]   [Full Text] [Related]  

  • 19. Adverse drug reactions reporting at a referral hospital in Zimbabwe.
    Khoza S; Madungwe I; Nyambayo P; Mthethwa J; Chikuni O
    Cent Afr J Med; 2004; 50(11-12):104-7. PubMed ID: 16615658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear medicine facility survey: SNM 2003 survey reporting on 2002 cost and utilization.
    Merlino DA
    J Nucl Med Technol; 2004 Dec; 32(4):215-9. PubMed ID: 15576344
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.